After completing of this activity, participants should be better able to:

• Summarize the prevalence and the social and economic burden and consequences of adolescent into adulthood ADHD

• Discuss the use of screening instruments to aid in detecting ADHD in adolescent into adulthood patients

• List the available treatments for adolescent into adulthood ADHD and their associated risks and benefits

• Discuss the clinical applicability of recent studies on ADHD in adolescent into adulthood populations

Educational Method

This activity consists of a downloadable slide presentation with audio.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and SynerMed® Communications. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1 AMA PRA Category .75  Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr Joseph Biederman receives research support from the following sources: Abbott Laboratories, Bristol-Myers Squibb, Cephalon Inc, Eli Lilly and Company, Eli Lilly and Company Foundation, Janssen, McNeil-PPC Inc, National Institute of Child Health and Human Development, National Institute of Mental Health, National Institute on Drug Abuse, Neurosearch, New River Pharmaceuticals, Novartis, Pfizer Inc, Prechter Foundation, Shire Pharmaceuticals, and Stanley Medical Research Institute. Dr Biederman is a speaker for the following speaker’s bureaus: Cephalon Inc, Eli Lilly and Company, McNeil-PPC Inc, Shire Pharmaceuticals, UCB Pharma Inc, Novartis. Dr Biederman is on the advisory board for the following pharmaceutical companies: Cephalon Inc, Eli Lilly and Company, Janssen, McNeil-PPC Inc, Novartis, and Shire Pharmaceuticals.

Dr Peter Jensen receives research support from McNeil-PPC Inc, and has an ownership interest in Eli Lilly and Company. He is a speaker for the following speaker’s bureaus: Janssen-Ortho Inc, McNeil-PPC Inc, and UCB Pharma. He is a consultant for Janssen Pharma, McNeil-PPC Inc, Novartis, and UCB Pharma.

Dr James McCracken is on the advisory board and speaker’s bureau for, and received research support from Abbott Laboratories, Bristol-Myers Squibb, Cephalon Inc, Eli Lilly and Company, Janssen, Johnson & Johnson, McNeil-PPC Inc, Novartis, Noven Pharmaceuticals Inc, Pfizer Inc, Shire Pharmaceuticals, UCB Pharmaceuticals, and Wyeth.

Dr Thomas Spencer (insert disclosure info when Jane gets it from PIM)

Dr Timothy Wilens receives grant support from Abbott Laboratories, Eli Lilly and Company, Ortho-McNeil, National Institute on Drug Abuse (NIDA), Neurosearch, and Shire Laboratories Inc. Dr Wilens is a speaker for the following speaker’s bureaus: Novartis Pharmaceuticals, Ortho-McNeil, and Shire Laboratories Inc. Dr Wilens is a consultant for Abbott Laboratories, Cephalon, Eli Lilly and Company, Glaxo-Smith Kline, Janssen, National Institute on Drug Abuse (NIDA), National Institute on Mental Health (NIMH), Novartis,
Ortho-McNeil, Pfizer, Saegis, Sanofi-Synthelabo, and Shire Laboratories Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Method of Participation

There are no fees for participating and receiving CME credit for this activity. During the period January, 2007 through January 31, 2008, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks.

Media

Slides with audio.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Postgraduate Institute for Medicine (PIM), SynerMedÒ Communications, and McNeil Pediatrics, Division of McNeil-PPC, Inc. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, SynerMed Communications and McNeil Pediatrics, Division of McNeil-PPC, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers of use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.